Clinical Trial

A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD

Study acronym: PAIVED
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
A total of 18,000 eligible subjects (or 6,000 subject distributed evenly between the 3 study arms) will be enrolled. Eligible subjects will be randomized in 1:1:1 (cell-culture-based vaccine, the recombinant vaccine, or the egg-based vaccine) over four influenza seasons (2018-2019, 2019-2020, 2020-2021, and 2021-2022).
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2018-11-06; most recent amendment 2026-03-13.
Status change: Recruiting → Active, Not Recruiting 2022-12-12
Status change: Not Yet Recruiting → Recruiting 2018-11-15
Trial Details
NCT Number NCT03734237
Lead Sponsor Henry M. Jackson Foundation for the Advancement of Military Medicine
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), Food and Drug Administration (FDA), US Department of Defense Armed Forces Health Surveillance Center, Naval Health Research Center, United States Air Force School of Aerospace Medicine, Uniformed Services University of the Health Sciences, Defense Health Agency
Conditions Influenza, Influenza-like Illness, Influenza Vaccines
Enrollment 15,448 participants
Start Date 2018-11-06
Primary Completion 2022-07-07 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-02